Journal of Surgery Concepts & Practice >

2022 , Vol. 27 >Issue 04: 370 - 374

DOI: https://doi.org/10.16139/j.1007-9610.2022.04.020

Review

Recent advance in neoadjuvant chemotherapy for rectal cancer

Expand
  • Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China

Received date: 2021-05-31

  Online published: 2022-09-20

Fold

Abstract

Rectal cancer is an important global public health problem and a huge economic burden. The clinical guideline was recommended by the National Comprehensive Cancer Network in America that neoadjuvant chemoradiothe-rapy, total mesorectal excision, postoperative adjuvant chemotherapy is the standard treatment for the patients with locally advanced rectal cancer. Neoadjuvant chemotherapy is an emerging option that has not yet been widely applied in the treatment of rectal cancer. In theory, this strategy is supposed to avoid the toxin of radiotherapy and increase patient survival. Neoadjuvant chemotherapy in rectal cancer was reviewed in this article including the development, basic theory, treatment strategy and course, compliance, adverse reactions and efficacy assessment, the direction of future optimization was explored.

Key words： Rectal cancer; Neoadjuvant therapy; Chemotherapy; Radiotherapy

Cite this article

GUO Yang, GUO Tian′an, XU Ye . Recent advance in neoadjuvant chemotherapy for rectal cancer[J]. Journal of Surgery Concepts & Practice, 2022 , 27(04) : 370 -374 . DOI: 10.16139/j.1007-9610.2022.04.020

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] 王红, 曹梦迪, 刘成成, 等. 中国人群结直肠癌疾病负担:近年是否有变?[J]. 中华流行病学杂志, 2020, 41(10):1633-1642.
[3] Favoriti P, Carbone G, Greco M, et al. Worldwide burden of colorectal cancer: a review[J]. Updates Surg, 2016, 68(1):7-11.
[4] 中华人民共和国国家卫生健康委员会. 中国结直肠癌诊疗规范(2020年版)[J]. 中华外科杂志, 2020, 58(8):561-585.
[5] Benson AB, Venook AP, Al-Hawary MM, et al. NCCN guidelines insights: rectal cancer, version 6.2020[J]. J Natl Compr Canc Netw, 2020, 18(7):806-815.
[6] Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer[J]. Lancet, 1986, 1(8496):1479-1482.
[7] Swedish Rectal Cancer T, Cedermark B, Dahlberg M, et al. Improved survival with preoperative radiotherapy in resectable rectal cancer[J]. N Engl J Med, 1997, 336(14):980-987.
[8] Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer[J]. N Engl J Med, 2001, 345(9):638-646.
[9] Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer[J]. New Engl J Med, 2004, 351(17):1731-1740.
[10] 王锡山. 2008至2012年美国国立综合癌症网络结直肠癌临床实践指南变化历程解读[J/CD]. 中华结直肠疾病电子杂志, 2012, 1(1):6-11.
[11] Morton UKD, Seymour M, Magill L, et al. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial[J]. Lancet Oncol, 2012, 13(11):1152-1160.
[12] Karoui M, Rullier A, Luciani A, et al. Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage Ⅱ and Ⅲ colon cancers: a multicentre randomised controlled phase Ⅱ trial - the PRODIGE 22-ECKINOXE trial[J]. Bmc Cancer, 2015, 15:511.
[13] Jakobsen A, Andersen F, Fischer A, et al. Neoadjuvant chemotherapy in locally advanced colon cancer. a phase Ⅱ trial[J]. Acta Oncol, 2015, 54(10):1747-1753.
[14] Liu F, Yang L, Wu Y, et al. CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase Ⅱ trial[J]. Chin J Cancer Res, 2016, 28(6):589-597.
[15] Fernandez-Martos C, Brown G, Estevan R, et al. Pre-operative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 phase Ⅱ multicenter trial[J]. Oncologist, 2014, 19(10):1042-1043.
[16] Patel UB, Brown G, Machado I, et al. MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial[J]. Ann Oncol, 2017, 28(2):344-353.
[17] Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial[J]. J Clin Oncol, 2014, 32(6):513-518.
[18] Hasegawa S, Goto S, Matsumoto T, et al. A multicenter phase 2 study on the feasibility and efficacy of neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer[J]. Ann Surg Oncol, 2017, 24(12):3587-3595.
[19] Koike J, Funahashi K, Yoshimatsu K, et al. Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage Ⅱ/Ⅲ rectal cancer: the FACT trial[J]. Cancer Chemoth Pharm, 2017, 79(3):519-525.
[20] Zhang JW, Huang MJ, Cai Y, et al. Neoadjuvant chemotherapy with mFOLFOXIRI without routine use of radiotherapy for locally advanced rectal cancer[J]. Clin Colorectal Canc, 2019, 18(4):238-244.
[21] Toritani K, Watanabe J, Suwa Y, et al. A prospective, single-arm, multicenter trial of neoadjuvant chemotherapy with mFOLFOX6 plus panitumumab without radiotherapy for locally advanced rectal cancer[J]. Int J Colorectal Dis, 2020, 35(12):2197-2204.
[22] Cienfuegos JA, Rodriguez J, Baixauli J, et al. Neoadjuvant chemotherapy without radiotherapy for patients with locally advanced rectal cancer. Oncologic outcomes[J]. Rev Esp Enferm Dig, 2020, 112(1):16-22.
[23] Deng YH, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase Ⅲ trial[J]. J Clin Oncol, 2016, 34(27):3300-3307.
[24] Deng YH, Chi P, Lan P, et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial[J]. J Clin Oncol, 2019, 37(34):3223-3233.
[25] Sun W, Dou R, Chen J, et al. Impact of long-course neoadjuvant radiation on postoperative low anterior resection syndrome and quality of life in rectal cancer: post hoc analysis of a randomized controlled trial[J]. Ann Surg Oncol, 2019, 26(3):746-755.
[26] Huang M, Lin J, Yu X, et al. Erectile and urinary function in men with rectal cancer treated by neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy alone: a randomized trial report[J]. Int J Colorectal Dis, 2016, 31(7):1349-1357.
[27] Schrag D, Weiser M, Saltz L, et al. Challenges and solutions in the design and execution of the PROSPECT Phase Ⅱ/Ⅲ neoadjuvant rectal cancer trial (NCCTGN 1048/Alliance)[J]. Clin Trials, 2019, 16(2):165-175.
[28] Sclafani F, Cunningham D. Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer[J]. Future Oncol, 2014, 10(14):2243-2257.
[29] Marijnen CAM, van de Velde CJH, Putter H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial[J]. J Clin Oncol, 2005, 23(9):1847-1858.
[30] Massaras D, Pantiora E, Sotirova E, et al. Neoadjuvant chemoradiotherapy in rectal cancer and anorectal sphincter dysfunction: review of the literature[J]. J Buon, 2020, 25(1):35-39.
[31] Sipaviciute A, Sileika E, Burneckis A, et al. Late gastrointestinal toxicity after radiotherapy for rectal cancer: a systematic review[J]. Int J Colorectal Dis, 2020, 35(6):977-983.
[32] Miwa K, Oki E, Enomoto M, et al. Randomized phase Ⅱ study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)[J]. BMC Cancer, 2021, 21(1):23.
[33] Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer[J]. New Engl J Med, 2006, 355(11):1114-1123.
[34] Jalil O, Claydon L, Arulampalam T. Review of neoadjuvant chemotherapy alone in locally advanced rectal cancer[J]. J Gastrointest Cancer, 2015, 46(3):219-236.
[35] Kalisz KR, Enzerra MD, Paspulati RM. MRI evaluation of the response of rectal cancer to neoadjuvant chemoradiation therapy[J]. Radiographics, 2019, 39(2):538-556.
[36] Wang XH, Liu ZJ, Xu JB, et al. Baseline and early 3D-CUBE volume reconstruction of locally advanced rectal cancer to predict tumor response after neoadjuvant chemotherapy[J]. J X-Ray Sci Technol, 2020, 28(2):231-241.
[37] Nishie A, Asayama Y, Ishigami K, et al. Amide proton transfer imaging to predict tumor response to neoadjuvant chemotherapy in locally advanced rectal cancer[J]. J Gastroen Hepatol, 2019, 34(1):140-146.
[38] Li ZY, Wang XD, Li M, et al. Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer[J]. World J Gastroentero, 2020, 26(19):2388-2402.
[39] Zhang JW, Cai Y, Hu HB, et al. Nomogram basing pre-treatment parameters predicting early response for locally advanced rectal cancer with neoadjuvant chemotherapy alone: a subgroup efficacy analysis of FOWARC study[J]. Oncotarget, 2016, 7(4):5053-5062.
[40] He F, Yu L, Ding Y, et al. Effects of neoadjuvant chemotherapy with or without intensity-modulated radiotherapy for patients with rectal cancer[J]. Cancer Sci, 2020, 111(11):4205-4217.
[41] Oi H, Okuyama T, Miyazaki S, et al. CD133 expression predicts relapse in patients with locally advanced rectal cancer treated with neoadjuvant chemotherapy[J]. In Vivo, 2021, 35(1):437-445.
Options
Outlines

/

〈 〉